BFM
TCRX icon

Boothbay Fund Management’s TScan Therapeutics TCRX Stock Holding History

Boothbay Fund Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$757K Buy
+772,241
New +$823K 0.01% 1259
2025
Q3 		– Sell
-24,363
Closed -$35.3K – 2156
2025
Q2 		$35.3K Buy
24,363
+8,121
+50% +$11.7K ﹤0.01% 1374
2025
Q1 		$22.4K Buy
+16,242
New +$35.1K ﹤0.01% 1329
2024
Q1 		– Sell
-13,293
Closed -$77.5K – 1924
2023
Q4 		$77.5K Buy
+13,293
New +$60.9K ﹤0.01% 1462

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Boothbay Fund Management's TCRX Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in TScan Therapeutics (TCRX) in Q2 2026: 772,241 shares worth $757K. The stake represents 0.01% of the portfolio and ranks #1259 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in TCRX as recently as Q2 2025.

Boothbay Fund Management first reported a position in TCRX in Q4 2023 and has held it in 4 quarters since. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Boothbay Fund Management held 772,241 shares of TScan Therapeutics worth $757K as of Q2 2026.
  • TScan Therapeutics was a new Boothbay Fund Management position in Q2 2026.
  • TScan Therapeutics made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1259 holding.
  • Boothbay Fund Management first reported a position in TScan Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.